Eleni Efstathiou is Associate Professor of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, USA. She is a world-renowned scientist whose research focuses on tissue-based translational research in prostate cancer. Clinically, she is one of the few physicians with practices on both sides of the Atlantic and extensive experience across the spectrum of genitourinary (GU) medical oncology.
Dr Efstathiou is currently Director of the Clinical Research Group, which is dedicated to driving high-impact research paired with outstanding patient care. Her goal is to combine the advantages of academia with those of private care thus offering the best possible care and treatment planning to cancer patients. She has also established and directs a very successful clinical site affiliated to the MD Anderson Cancer Center within the Athens Medical Centre; this is a site of excellence in GU oncology that, as well as caring for patients, also pursues access to cutting edge clinical research.
Dr Efstathiou’s main research has been novel androgen signalling inhibition treatment as a tool to guide marker-driven treatment strategies in prostate cancer, and genomic and non-genomic pathways of resistance. She has developed and directs two research laboratories: the Stanford Alexander tissue and derivatives laboratory, which is highly specialised in tissue processing and molecular interrogation; and the Eckstein laboratory, which focuses on the interaction between clinic and patient, and collects tissue and other research samples.
Over the past 9 years, Dr Efstathiou has developed two major clinical trial platforms in the bone metastatic setting and locally advanced disease setting, respectively, and has been performing ‘companion’ studies exploring the impact of novel therapeutic agents on the tumour microenvironment and associating with pre-treatment molecular characteristics. She is currently testing and validating proposed predictive signatures and is the biomarker PI for two large Phase III trials testing the advantage of combinatorial androgen signalling inhibition in advanced prostatic carcinoma. Furthermore, the two laboratories she leads are providing support for tissue-based research, including the Prostate Spore and Moon Shots Program. She has also engaged in multiple collaborations outside her current institution.
Dr Efstathiou is the recipient of a Young Investigator Award and a Career Development Award by the Prostate Cancer Foundation and a PI on a PCF Challenge Award. She is a European Society of Medical Oncology (ESMO) Academy faculty member and a founding and scientific committee member of the APCCC St Gallen Consensus Meeting for Prostate Cancer. She has published more than 120 manuscripts in peer-reviewed journals. Of note, she is the only physician scientist to present her work orally at six consecutive American Society of Clinical Oncology annual meetings. She also served as the Chair of the GU Scientific Committee for congress and remains an ESMO committee member.
Being among the first physician scientists to engage prospectively in prostate cancer tissue-based research and to identify candidate pathways of resistance and feedback to novel treatments, she is an international expert spearheading therapy development strategy in prostate cancer.
EM-06830 - Date of preparation: March 2019